# Pinetree Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/pinetree-therapeutics

- Industry: Biotechnology
- Headquarters: Cambridge, US
- Website: www.pinetreetx.com
- Total disclosed funding: $71M
- Latest round: Series B (Oct 28, 2025)
- Investors on record: 14

## About

Founded in 2019 and based in Massachusetts, US, Pinetree Therapeutics, Inc. operates as a preclinical stage biotechnology company that uses TAER-TAB technology, a bispecific antibody (bsAb) that targets cancer cells in the lungs, breasts, pancreas, cervix, colon, kidneys, ovaries, stomach, and others. In October 2025, Pinetree Therapeutics, Inc. raised USD 47 million in series B funding from returning investors DSC Investment, WIDWIN Investment, STIC Ventures, Samho Green Investment, Atinum Investment, S&S Investment, SJ Investment Partners, Smilegate Investment, and Gauss Capital Management, with participation from individual and other unspecified investors.

The company's therapeutical services are based on technology TAER-TAB (Tumour Associated Essential Receptor Targeting Antibody), a platform technology that can be used to create multifunctional antibodies directed against multiple receptor targets on cancer cells, and ViTRAP (Virus Targeting Recombinant Agent Platform), an antiviral technology which can design discrete, disease-specific, biologic therapeutics for many diseases with unmet needs on a global basis.

The company will use the funding to advance research, develop new products, and support collaborations.

## Funding rounds

- Series B, Oct 28, 2025, $47M — Atinum Investment, Korea Investment Partners, Smilegate Investment, DSC Investment, Samho Green Investment, SV Investment, SJ Investment Partners, Widwin Investment, STIC Ventures, Gauss Capital, S&S Investment
- Series A, Jun 7, 2022, $24M — InterVest, DSC Investment, Samho Green Investment, SJ Investment Partners, SK Securities, J Curve Investment

## Investors

- InterVest (https://capitalatlas.ai/funds/intervest) — Series A
- DSC Investment (https://capitalatlas.ai/funds/dsc-investment) — Series A, Series B
- Samho Green Investment (https://capitalatlas.ai/funds/samho-green-investment) — Series A, Series B
- SJ Investment Partners (https://capitalatlas.ai/funds/sj-investment-partners) — Series A, Series B
- SK Securities — Series A
- J Curve Investment (https://capitalatlas.ai/funds/j-curve-investment) — Series A
- Atinum Investment (https://capitalatlas.ai/funds/atinum-investment) — Series B
- Korea Investment Partners (https://capitalatlas.ai/funds/korea-investment-partners) — Series B
- Smilegate Investment (https://capitalatlas.ai/funds/smilegate-investment) — Series B
- SV Investment (https://capitalatlas.ai/funds/sv-investment) — Series B
- Widwin Investment (https://capitalatlas.ai/funds/widwin-investment) — Series B
- STIC Ventures (https://capitalatlas.ai/funds/stic-ventures) — Series B
- Gauss Capital — Series B
- S&S Investment (https://capitalatlas.ai/funds/s-s-investment) — Series B